IPA
Price
$0.47
Change
+$0.03 (+6.82%)
Updated
Apr 24, 04:57 PM (EDT)
Capitalization
21.23M
LPCN
Price
$3.17
Change
+$0.07 (+2.26%)
Updated
Apr 24, 04:48 PM (EDT)
Capitalization
17.01M
Ad is loading...

IPA vs LPCN

Header iconIPA vs LPCN Comparison
Open Charts IPA vs LPCNBanner chart's image
ImmunoPrecise Antibodies
Price$0.47
Change+$0.03 (+6.82%)
Volume$191
Capitalization21.23M
Lipocine
Price$3.17
Change+$0.07 (+2.26%)
Volume$344
Capitalization17.01M
IPA vs LPCN Comparison Chart
Loading...
IPA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LPCN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IPA vs. LPCN commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IPA is a StrongBuy and LPCN is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (IPA: $0.44 vs. LPCN: $3.10)
Brand notoriety: IPA and LPCN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IPA: 31% vs. LPCN: 38%
Market capitalization -- IPA: $21.23M vs. LPCN: $17.01M
IPA [@Biotechnology] is valued at $21.23M. LPCN’s [@Biotechnology] market capitalization is $17.01M. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IPA’s FA Score shows that 1 FA rating(s) are green whileLPCN’s FA Score has 0 green FA rating(s).

  • IPA’s FA Score: 1 green, 4 red.
  • LPCN’s FA Score: 0 green, 5 red.
According to our system of comparison, IPA is a better buy in the long-term than LPCN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IPA’s TA Score shows that 6 TA indicator(s) are bullish while LPCN’s TA Score has 7 bullish TA indicator(s).

  • IPA’s TA Score: 6 bullish, 2 bearish.
  • LPCN’s TA Score: 7 bullish, 1 bearish.
According to our system of comparison, LPCN is a better buy in the short-term than IPA.

Price Growth

IPA (@Biotechnology) experienced а +3.98% price change this week, while LPCN (@Biotechnology) price change was +2.99% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.94%. For the same industry, the average monthly price growth was -5.37%, and the average quarterly price growth was -12.15%.

Reported Earning Dates

IPA is expected to report earnings on Mar 28, 2025.

LPCN is expected to report earnings on Aug 09, 2023.

Industries' Descriptions

@Biotechnology (+7.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IPA($21.2M) has a higher market cap than LPCN($17M). IPA YTD gains are higher at: 7.846 vs. LPCN (-36.475). LPCN has higher annual earnings (EBITDA): -3.68M vs. IPA (-45.11M). LPCN has more cash in the bank: 19.8M vs. IPA (12.9M). LPCN has less debt than IPA: LPCN (1.48M) vs IPA (12.9M). IPA has higher revenues than LPCN: IPA (24M) vs LPCN (7.92M).
IPALPCNIPA / LPCN
Capitalization21.2M17M125%
EBITDA-45.11M-3.68M1,226%
Gain YTD7.846-36.475-22%
P/E RatioN/AN/A-
Revenue24M7.92M303%
Total Cash12.9M19.8M65%
Total Debt12.9M1.48M870%
FUNDAMENTALS RATINGS
IPA vs LPCN: Fundamental Ratings
IPA
LPCN
OUTLOOK RATING
1..100
2957
VALUATION
overvalued / fair valued / undervalued
1..100
23
Undervalued
42
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9692
PRICE GROWTH RATING
1..100
6488
P/E GROWTH RATING
1..100
10096
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IPA's Valuation (23) in the null industry is in the same range as LPCN (42) in the Pharmaceuticals Other industry. This means that IPA’s stock grew similarly to LPCN’s over the last 12 months.

IPA's Profit vs Risk Rating (100) in the null industry is in the same range as LPCN (100) in the Pharmaceuticals Other industry. This means that IPA’s stock grew similarly to LPCN’s over the last 12 months.

LPCN's SMR Rating (92) in the Pharmaceuticals Other industry is in the same range as IPA (96) in the null industry. This means that LPCN’s stock grew similarly to IPA’s over the last 12 months.

IPA's Price Growth Rating (64) in the null industry is in the same range as LPCN (88) in the Pharmaceuticals Other industry. This means that IPA’s stock grew similarly to LPCN’s over the last 12 months.

LPCN's P/E Growth Rating (96) in the Pharmaceuticals Other industry is in the same range as IPA (100) in the null industry. This means that LPCN’s stock grew similarly to IPA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IPALPCN
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
89%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 15 days ago
85%
Declines
ODDS (%)
Bearish Trend 24 days ago
90%
Bearish Trend 8 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
81%
View a ticker or compare two or three
Ad is loading...
IPA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LPCN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CCLD1.530.12
+8.51%
CareCloud
CAMT63.973.78
+6.28%
Camtek Ltd
SWKH19.220.22
+1.16%
SWK Holdings Corp
BLDR117.261.16
+1.00%
Builders FirstSource
RSKD4.530.02
+0.44%
Riskified Ltd